SECsense Logo

Eupraxia Pharmaceuticals Inc. Reports February 2025 Form 6-K Filing

$EPRX
Form 6-K
Filed on: 2025-02-25
Source
Eupraxia Pharmaceuticals Inc. Reports February 2025 Form 6-K Filing

Key Information Extracted from the Financial Report (Form 6-K)

  1. Filing Type and Date:
  • Form Type: 6-K
  • Filing Date: February 25, 2025
  • Reporting Period: For the month of February 2025
  1. Company Information:
  • Company Name: Eupraxia Pharmaceuticals Inc.
  • Address:
    • 201-2067 Cadboro Bay Road
    • Victoria, British Columbia, Canada V8R 5G4
  • Telephone: (250) 590-3968
  1. SEC Information:
  • Commission File Number: 001-41923
  1. Annual Report Filing:
  • The company indicates it will file annual reports under Form 40-F.
  1. Included Documents:
  • The report includes a Press Release dated February 25, 2025. The document is referenced as Exhibit 99.1.
  1. Signatures:
  • Date of Signature: February 25, 2025
  • Signed By:
    • Name: Alex Rothwell
    • Title: Chief Financial Officer

Insights:

  • Eupraxia Pharmaceuticals Inc. is complying with SEC regulations by submitting this Form 6-K as a foreign private issuer.
  • The filing date and reporting month indicate timely compliance with necessary reporting requirements.
  • The indication that the company will file annual reports under Form 40-F suggests it operates under Canadian regulations alongside U.S. filing requirements.
  • The presence of a press release could imply significant news or updates pertinent to investors or stakeholders, warranting further examination.

This summary highlights the essential details for stakeholders looking to assess Eupraxia Pharmaceuticals' regulatory compliance and operational transparency.